KYNB · Kyntra Bio, Inc.

Kyntra Bio reported first quarter 2026 financial results, with total revenue increasing to $3.7 million from $2.7 million in the same period last year, driven by drug product revenue of $3.5 million. Net loss from continuing operations narrowed to $15.1 million ($3.74 per share) from $16.8 million ($4.15 per share) a year ago, reflecting lower operating expenses. Research and development expenses decreased to $7.6 million from $9.2 million, while selling, general and administrative expenses fell to $5.9 million from $8.1 million. The company ended the quarter with $100.3 million in cash, cash equivalents, investments, and accounts receivable, providing a cash runway into 2028. On the pipeline front, the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and on track for an interim analysis in the fourth quarter of 2026. Positive results from an investigator-sponsored study of FG-3246 in combination with enzalutamide were presented at ASCO GU 2026, showing a median radiographic progression-free survival of 7.0 months overall and 10.1 months in patients who progressed on only one prior androgen receptor pathway inhibitor. The company is also finalizing the pivotal Phase 3 trial protocol for roxadustat in lower-risk myelodysplastic syndromes following FDA feedback, with trial initiation expected in the second half of 2026. Management expressed confidence in the pipeline progress and financial position.